300584 Nanjing Hicin Pharmaceutical
- 19.76
- +0.40+2.07%
Nanjing Hicin Pharmaceutical News
Haichen Pharmaceutical (300584): Torasemide growth falls, focus on the subsequent layout of high-end generic drugs and innovative drugs
Haichen Pharmaceutical Co., Ltd. (300584): the research and development of its own varieties of NMS with abundant injection pipeline is advancing steadily.
Haichen Pharmaceutical (300584) Quarterly report comments: the performance is affected by Torasemi's high base and the coordinated development of NMS is still worthy of attention.
Haichen Pharmaceutical (300584) in-depth report: coordinate with NMS to open the curtain of innovation + high-end imitation + multi-wheel drive of APIs
Haichen Pharmaceutical Co., Ltd. (300584): Torasemi maintains advantages and rapid growth of second-tier products
Haichen Pharmaceutical Co., Ltd. (300584): sales of core products continue to grow rapidly and introduce innovative drugs overseas for the first time to open a new chapter in innovation transformation.
Haichen Pharmaceutical (300584) semi-annual report Review: work with NMS to open the curtain of innovative drugs + high-end generic two-wheel drive
Haichen Pharmaceutical (300584): sustained High growth of generic drugs NMS promotes Innovation and Transformation
Haichen Pharmaceutical Co., Ltd. (300584): the performance is in line with the expected sales expense rate.
Haichen Pharmaceutical (300584) Quarterly report comments: the first quarter results are in line with the expected high growth of R & D investment
Haichen Pharmaceutical (300584): Revenue increased dramatically and R&D progressed steadily
海辰药业(300584)：核心品种持续放量 高端仿制药望接连落地
海辰药业(300584)2018年业绩快报点评：研发投入加速扩张下业绩符合预期 创新转型落地期即将到来
海辰药业(300584)：2018年业绩符合预期 NMS启动A轮融资
海辰药业(300584)：业绩符合预期 主打产品快速增长
海辰药业(300584)深度研究：“小而全”的明日之星
海辰药业(300584)点评：NMS研发实力雄厚 赴港上市提升估值
海辰药业(300584)：NMS研发管线惊艳亮相 赴港上市流程已启动
海辰药业(300584)三季报点评：业绩符合预期 关注NMS研发进展
海辰药业(300584)季报点评：收入快速增长 业绩符合预期
Analysis
Price Target
No Data
